Human Genome Editing and Sickle Cell Disease in Canada: Urgent and Unresolved Ethical Considerations
DOI:
https://doi.org/10.7202/1117873arKeywords:
Casgevy, equity, inclusion, ethics, human genome editing, justice, public engagement, sickle cell diseaseLanguage(s):
EnglishAbstract
Some countries are already approving therapeutic applications of human genome editing. For example, recently the United Kingdom and USA have approved Casgevy as part of a treatment protocol for sickle cell disease. Should Canada follow this lead? Here we discuss the most important, yet unresolved, ethical issues in a Canadian context, and argue that much more public engagement and deliberation is needed.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Maria Klimenko, Ryan Tonkens
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Canadian Journal of Bioethics applies the Creative Commons Attribution 4.0 International License to all its publications. Authors therefore retain copyright of their publication, e.g., they can reuse their publication, link to it on their home page or institutional website, deposit a PDF in a public repository. However, the authors allow anyone to download, reuse, reprint, distribute, and/or copy their publication, so long as the original authors and source are cited.
_smaller.png){kind=logo}
